Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 2 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. WO 2025198916

    ANTICORPS ANTI-TAU

    ABBVIE INC [US] · Granted Sep 25, 2025 · Expires Sep 20, 2045

    granted
  2. US 12421292

    Anti-DLL3 chimeric antigen receptors and uses thereof

    Legend Biotech Ireland Limited · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  3. US 12421308

    Anti-G-CSF antibodies and uses thereof

    ME Therapeutics Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  4. US 12421317

    Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  5. US 12415867

    Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

    The Board of Regents of the University of Oklahoma · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  6. WO 2025186043

    FORMULATION PHARMACEUTIQUE POUR ANTICORPS ANTI-CCR8

    BAYER AG [DE] · Granted Sep 12, 2025 · Expires Sep 7, 2045

    granted
  7. US 12403167

    Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament

    OCEAN UNIVERSITY OF CHINA · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  8. US 12398123

    Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria

    United States Government as represented by the Department of Veterans Affairs · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  9. US 12391750

    Anti-C1S antibodies and methods of use thereof

    Bioverativ USA Inc. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  10. US 12391742

    Anti-KRAS-G12D T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  11. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  12. US 12384845

    Activatable masked anti-CTLA4 binding proteins

    Xilio Development, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  13. US 12383572

    Administration of an anti-activin-a compound to a subject

    Atara Biotherapeutics, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  14. US 12378193

    Anti-arrhythmicity agents

    The Regents of the University of California · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  15. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  16. US 12371434

    MLL1 inhibitors and anti-cancer agents

    CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  17. US 12371499

    Method of treating cancer using anti-AV8 antibodies

    The Regents of the University of California · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  18. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  19. US 12371506

    Subcutaneous administration of anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  20. US 12365723

    Human plasma-derived IGG preparation enriched in anti-parvo B19 natural IGGS

    Takeda Pharmaceutical Company Limited · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  21. US 12365729

    Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis

    Disc Medicine, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  22. US 12357586

    Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  23. US 12357703

    Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping

    Dyne Therapeutics, Inc. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  24. US 12357617

    Discovery of novel anti-infectives for gram negative pathogens

    The Regents of the University of California · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted